Therapy is based on ACD856’s indicative disease modifying effects against the condition
News
Kite’s Yescarta to receive European marketing authorisation
First treatment in 30 years to improve second-line treatment of DLBCL
Parliament square set for ME research demonstration
Demonstrators will demand hundreds of millions of pounds ‘missing’ from ME research
NHS Confederation responds to the appointment of Jeremy Hunt
New Chancellor of the Exchequer left in no doubt regarding challenges ahead
XBiotech enrols first patient in Natrunix study
Therapy involves patients with colorectal cancer at 20 medical centres
Patient recruitment completed in Tourette syndrome study
Research has demonstrated a strong safety prolife and reduced tics among participants
3.2m UK birds culled as record avian flu cases increase
Virus can be lethal to humans and its spread is likely to accelerate this winter
PharmaLex seals merger with UK’s NeoHealthHub
Agreement will be key to building a pan-European market access practice
Liverpool city region wins government status for vaccine discovery
DIT to showcase Liverpool city region’s life sciences expertise which will also include manufacturing
Mission Street and BentallGreenOak to create 23-acre ‘science district’
Development will boost life sciences sector by delivering significant lab space in Cambridge
Positive results from trial of Arecor’s insulin candidate AT247
Therapy demonstrates significantly accelerated insulin absorption and early exposure
AlzeCure demonstrates disease-modifying effects of NeuroRestore ACD856
Data from the study shows that ACD856 has a potential neuroprotective effect in a cellular mode
Brainomix in collaboration with UK Government-funded NCIMI
Partnership will evaluate AI-powered technology in lung cancer care
LifeArc and MRC launch toolkit to navigate medicines repurposing
Medicines repurposing offers new avenues for treating a range of common and rare diseases
Ziphius vaccines and UZ Ghent establish vaccine collaboration
First EU public-private collaboration for production of saRNA-based vaccines
